BRISBANE, CA--(Marketwire -02/01/12)- GlobalEnglish Corporation (www.GlobalEnglish.com), the leading provider of on-demand software to advance Enterprise Fluency for global organizations, today announced that it has been selected by Novartis Vaccines & Diagnostics, the world's fifth-largest vaccines manufacturer and second-largest supplier of flu vaccines in the U.S., to support the global Business English communication needs of its employees. GlobalEnglish offers a solution to increase global companies' abilities to communicate and collaborate using Business English worldwide, leading to improved workforce productivity.
With an emphasis on innovative research and a strong commitment to preventing disease, Novartis Vaccines & Diagnostics, a division of Novartis, has led the healthcare industry with its global presence. Based in Italy, the division operates in more than 15 countries with more than 5000 employees representing nearly 50 different nationalities. In this environment, the ability for employees to communicate and collaborate effectively and efficiently in one common language -- Business English -- is vital to sustaining the success of Novartis' Vaccines & Diagnostics global operations and to advancing healthcare innovation.
In today's global economy, multinational organizations urgently need a way for globally dispersed teams to put their Business English skills to work immediately and to collaborate with each other on a common platform. 70 percent of learning is done while working according to research by Michael M. Lombardo and Robert W. Eichinger for the Center for Creative Leadership. On-the-job and socially-driven training lets employees learn while doing, diminishing company investment, increasing critical job skills more rapidly, and driving better organizational performance.
"At Novartis Vaccines & Diagnostics, we engage in high-stakes research and testing, and are responsible for 60 percent of Novartis Group's total vaccine production," says Gianluca Magnani, Director of Human Resources at Novartis Vaccines & Diagnostics. "The need to communicate efficiently and accurately is vital for the success of our company. It makes sense that we would offer GlobalEnglish's Business English support tools to each employee to enhance communications across departments and functions."
Novartis Vaccines & Diagnostics has quickly grown to become a leading employer of choice in the pharmaceutical industry, and has won recognition for being one of Europe's best places to work by Fortune, Institute Italia, The Scientist, and many others. This leadership position is largely due to the Company offering employees the tools they need to fluidly work together.
"Our mission is to empower our employees by providing them with the necessary tools to do their jobs more effectively," states Gianluca. "GlobalEnglish has given us an opportunity to provide our entire organization with the tools to help us grow, prosper, and succeed."
GlobalEnglish offers complete support for global teams who collaborate across countries, cultures and time zones by providing targeted resources that increase employees' overall Business English proficiency as well as on-demand performance support tools that improve day-to-day productivity by helping employees instantly use English on the job.
"We are honored to partner with Novartis Vaccines & Diagnostics, a progressive company that understands the current and future demands of global business and the strategic solutions necessary to maintain a competitive edge," says Tom Kahl, President of GlobalEnglish Corporation. "Improving communication and collaboration across the globally integrated enterprise increases productivity and performance and produces massive ROI thanks to the time and money saved on individual tasks -- that's Enterprise Fluency™."
About GlobalEnglish Corporation
GlobalEnglish offers solutions for Enterprise Fluency™: the communication, collaboration, and operational proficiency companies must have to compete in today's global economy. Enterprise Fluency is the measure of a company's ability to apply their company-wide gains in Business English skills to improve the ease with which their global teams can communicate and collaborate with each other and the effectiveness with which the company can operate across country borders.
We have more than 500 enterprises partnering with us globally, including BNP Paribas, Capgemini, Cisco, Deloitte, GlaxoSmithKline, Hewlett-Packard, Hilton, John Deere, Procter & Gamble, and Unisys. Our comprehensive, on-demand software solution is available in 15 languages for instant, on-the-job support for business tasks in English -- such as writing emails -- and programs for building lasting Business English proficiency. Headquartered in Brisbane, California, we have global reach to support multinational companies in any country worldwide.
For more information, please visit www.GlobalEnglish.com.
About Novartis Vaccines & Diagnostics
Novartis Vaccines and Diagnostics is a division of Novartis, focused on the development of preventive treatments. The division has two businesses: Novartis Vaccines and Novartis Diagnostics. Novartis Vaccines is the world's fifth-largest vaccines manufacturer and second-largest supplier of flu vaccines in the US. The division's products also include meningococcal, pediatric and travel vaccines. Novartis Diagnostics, the blood testing business, is dedicated to preventing the spread of infectious diseases through the development of novel blood-screening tools that protect the world's blood supply. Located in Cambridge, Massachusetts, Novartis Vaccines and Diagnostics is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2010, the Group's continuing operations achieved net sales of USD 50.6 billion, while approximately USD 9.1 billion (USD 8.1 billion excluding impairment and amortization charges) was invested in R&D throughout the Group. Novartis Group companies employ approximately 121,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit http://www.novartis.com.